UroGen Pharma
URGN
NASDAQ
IPO2017
about URGN
UroGen Pharma specializes in developing innovative treatments for urological conditions, with a focus on its lead product Urolife, designed to alleviate lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $23.77 | $24.65 | $22.51 | $1.08B | 847.65K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.69 | n/a | n/a | -99.65% | -121.34% | 0% |